Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Alexa B Kimball , Gregor B E Jemec , Afsaneh Alavi , Ziad Reguiai , Alice B Gottlieb , Falk G Bechara , Carle Paul , Evangelos J Giamarellos Bourboulis , Axel P Villani , Andreas Schwinn , Franziska Ruëff , Larisha Pillay Ramaya , Adam Reich , Ines Lobo , Rodney Sinclair , Thierry Passeron , Antonio Martorell , Pedro Mendes-Bastos , Georgios Kokolakis , Pierre-Andre Becherel , Magdalena B Wozniak , Angela Llobet Martinez , Xiaoling Wei , Lorenz Uhlmann , Anna Passera , Deborah Keefe , Ruvie Martin , Clarice Field , Li Chen , Marc Vandemeulebroecke , Shoba Ravichandran , Elisa Muscianisi Lancet (London, England)（2023）
关键词
secukinumab, sunshine, moderate-to-severe, placebo-controlled, double-blind
AI 理解论文
溯源树
样例
